| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 42 | 2020 | 1362 | 4.840 |
Why?
|
| Orbit | 10 | 2023 | 205 | 4.000 |
Why?
|
| Hypoglycemic Agents | 20 | 2020 | 586 | 3.430 |
Why?
|
| Eyelids | 14 | 2023 | 163 | 3.350 |
Why?
|
| Lacrimal Apparatus Diseases | 9 | 2023 | 137 | 2.810 |
Why?
|
| Orbital Diseases | 6 | 2022 | 118 | 2.790 |
Why?
|
| Insulin Resistance | 19 | 2020 | 731 | 2.550 |
Why?
|
| Thiazolidinediones | 11 | 2015 | 148 | 2.470 |
Why?
|
| Conjunctival Neoplasms | 4 | 2022 | 120 | 2.250 |
Why?
|
| Oculomotor Muscles | 6 | 2019 | 179 | 2.140 |
Why?
|
| Blood Glucose | 27 | 2021 | 1244 | 1.960 |
Why?
|
| Orbital Neoplasms | 8 | 2022 | 224 | 1.960 |
Why?
|
| Eye Foreign Bodies | 5 | 2020 | 14 | 1.940 |
Why?
|
| Fatty Acids, Nonesterified | 18 | 2012 | 159 | 1.850 |
Why?
|
| Eyelid Neoplasms | 9 | 2019 | 191 | 1.810 |
Why?
|
| Blepharoptosis | 6 | 2018 | 70 | 1.700 |
Why?
|
| Exophthalmos | 5 | 2019 | 45 | 1.670 |
Why?
|
| Dermoid Cyst | 2 | 2023 | 38 | 1.580 |
Why?
|
| Sebaceous Gland Neoplasms | 7 | 2019 | 99 | 1.550 |
Why?
|
| Eye Injuries | 3 | 2019 | 57 | 1.440 |
Why?
|
| Eyelid Diseases | 4 | 2019 | 76 | 1.430 |
Why?
|
| Retinoblastoma | 6 | 2023 | 200 | 1.420 |
Why?
|
| Hemangioma, Capillary | 5 | 2021 | 35 | 1.420 |
Why?
|
| Adiponectin | 12 | 2017 | 163 | 1.400 |
Why?
|
| Dacryocystorhinostomy | 5 | 2023 | 44 | 1.390 |
Why?
|
| Lacrimal Apparatus | 5 | 2023 | 181 | 1.380 |
Why?
|
| Cysticercosis | 5 | 2021 | 31 | 1.320 |
Why?
|
| Retinal Neoplasms | 5 | 2023 | 144 | 1.310 |
Why?
|
| Venoms | 5 | 2012 | 23 | 1.280 |
Why?
|
| Orbital Pseudotumor | 2 | 2019 | 13 | 1.260 |
Why?
|
| Adipose Tissue | 4 | 2023 | 769 | 1.200 |
Why?
|
| Insulin | 19 | 2014 | 1454 | 1.190 |
Why?
|
| Jaw Abnormalities | 2 | 2018 | 4 | 1.180 |
Why?
|
| Hematoma | 2 | 2018 | 160 | 1.110 |
Why?
|
| Liver | 9 | 2018 | 2961 | 1.100 |
Why?
|
| Conjunctiva | 5 | 2020 | 250 | 1.090 |
Why?
|
| Lacrimal Duct Obstruction | 4 | 2023 | 53 | 1.080 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2019 | 17 | 1.050 |
Why?
|
| Muscle, Skeletal | 9 | 2014 | 1270 | 1.030 |
Why?
|
| Glucagon-Like Peptide 1 | 4 | 2013 | 67 | 0.990 |
Why?
|
| Eye Abnormalities | 2 | 2022 | 118 | 0.980 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 402 | 0.970 |
Why?
|
| Orbit Evisceration | 3 | 2022 | 46 | 0.950 |
Why?
|
| Diabetic Angiopathies | 3 | 2016 | 78 | 0.940 |
Why?
|
| Peptides | 6 | 2016 | 1479 | 0.920 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2023 | 36 | 0.920 |
Why?
|
| Humans | 135 | 2023 | 261506 | 0.900 |
Why?
|
| Ectropion | 1 | 2022 | 11 | 0.890 |
Why?
|
| Fraser Syndrome | 1 | 2022 | 1 | 0.880 |
Why?
|
| Facial Neoplasms | 1 | 2023 | 84 | 0.860 |
Why?
|
| Syndactyly | 1 | 2022 | 26 | 0.860 |
Why?
|
| Fistula | 1 | 2023 | 76 | 0.850 |
Why?
|
| Microphthalmos | 1 | 2022 | 57 | 0.840 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 500 | 0.830 |
Why?
|
| Microscopy, Acoustic | 2 | 2020 | 26 | 0.830 |
Why?
|
| Timolol | 2 | 2021 | 10 | 0.820 |
Why?
|
| Male | 95 | 2022 | 123000 | 0.820 |
Why?
|
| Eye Hemorrhage | 2 | 2020 | 3 | 0.800 |
Why?
|
| PPAR gamma | 6 | 2020 | 229 | 0.790 |
Why?
|
| Exoribonucleases | 1 | 2021 | 42 | 0.780 |
Why?
|
| Eye Neoplasms | 6 | 2021 | 247 | 0.770 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2020 | 21 | 0.770 |
Why?
|
| Wood | 1 | 2020 | 18 | 0.760 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2020 | 26 | 0.760 |
Why?
|
| Optic Nerve Injuries | 1 | 2020 | 12 | 0.760 |
Why?
|
| Lipid Metabolism | 5 | 2010 | 483 | 0.760 |
Why?
|
| Blepharophimosis | 2 | 2018 | 21 | 0.760 |
Why?
|
| Fatty Liver | 2 | 2013 | 235 | 0.740 |
Why?
|
| 14-3-3 Proteins | 1 | 2021 | 143 | 0.740 |
Why?
|
| Heart Defects, Congenital | 3 | 2018 | 1697 | 0.720 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2013 | 650 | 0.720 |
Why?
|
| Face | 1 | 2022 | 273 | 0.720 |
Why?
|
| Pyrazines | 4 | 2007 | 495 | 0.720 |
Why?
|
| Epidermal Cyst | 1 | 2019 | 46 | 0.700 |
Why?
|
| Tears | 2 | 2020 | 181 | 0.690 |
Why?
|
| Lighting | 1 | 2019 | 27 | 0.680 |
Why?
|
| Adhesives | 1 | 2018 | 12 | 0.670 |
Why?
|
| Lacerations | 1 | 2019 | 33 | 0.660 |
Why?
|
| Female | 78 | 2022 | 141928 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 5437 | 0.660 |
Why?
|
| Mouth Mucosa | 1 | 2019 | 216 | 0.650 |
Why?
|
| Glucose Clamp Technique | 8 | 2010 | 89 | 0.640 |
Why?
|
| Skin Abnormalities | 1 | 2018 | 23 | 0.640 |
Why?
|
| Ocular Motility Disorders | 1 | 2018 | 47 | 0.630 |
Why?
|
| Paracentesis | 2 | 2019 | 18 | 0.630 |
Why?
|
| Adult | 55 | 2023 | 77950 | 0.630 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.620 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 86 | 0.620 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2020 | 413 | 0.620 |
Why?
|
| Ocular Hypertension | 1 | 2017 | 24 | 0.610 |
Why?
|
| Neurilemmoma | 2 | 2018 | 127 | 0.610 |
Why?
|
| Incretins | 2 | 2018 | 25 | 0.600 |
Why?
|
| Inflammasomes | 5 | 2021 | 161 | 0.600 |
Why?
|
| Prospective Studies | 17 | 2023 | 12873 | 0.600 |
Why?
|
| PPAR alpha | 3 | 2017 | 62 | 0.580 |
Why?
|
| Decompression, Surgical | 1 | 2017 | 143 | 0.580 |
Why?
|
| Cardiovascular System | 1 | 2018 | 145 | 0.570 |
Why?
|
| Emphysema | 1 | 2017 | 87 | 0.570 |
Why?
|
| Muscle Proteins | 2 | 2013 | 549 | 0.570 |
Why?
|
| Cataract Extraction | 1 | 2018 | 184 | 0.560 |
Why?
|
| Needles | 1 | 2016 | 107 | 0.550 |
Why?
|
| Hypergammaglobulinemia | 1 | 2015 | 19 | 0.540 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 4053 | 0.540 |
Why?
|
| Abnormalities, Multiple | 1 | 2022 | 998 | 0.540 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 1021 | 0.540 |
Why?
|
| Prefrontal Cortex | 2 | 2017 | 229 | 0.540 |
Why?
|
| Young Adult | 23 | 2021 | 21445 | 0.530 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 37 | 0.530 |
Why?
|
| Child | 25 | 2023 | 29154 | 0.530 |
Why?
|
| Urogenital Abnormalities | 1 | 2018 | 174 | 0.530 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 286 | 0.520 |
Why?
|
| Metformin | 3 | 2014 | 378 | 0.520 |
Why?
|
| Middle Aged | 52 | 2021 | 86204 | 0.510 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2015 | 36 | 0.510 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2016 | 197 | 0.510 |
Why?
|
| Anus, Imperforate | 1 | 2014 | 10 | 0.510 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 39 | 0.500 |
Why?
|
| Radius | 1 | 2014 | 42 | 0.500 |
Why?
|
| Glucose | 7 | 2011 | 1248 | 0.500 |
Why?
|
| Tuberculosis, Ocular | 1 | 2014 | 4 | 0.490 |
Why?
|
| Hypolipidemic Agents | 4 | 2009 | 190 | 0.490 |
Why?
|
| Eye Infections, Parasitic | 3 | 2018 | 7 | 0.490 |
Why?
|
| Lipoxins | 3 | 2012 | 20 | 0.490 |
Why?
|
| Diseases in Twins | 1 | 2014 | 99 | 0.480 |
Why?
|
| Twins, Monozygotic | 1 | 2014 | 129 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2022 | 7551 | 0.470 |
Why?
|
| Uveal Neoplasms | 3 | 2020 | 176 | 0.460 |
Why?
|
| Glucosides | 3 | 2018 | 64 | 0.460 |
Why?
|
| Lipids | 3 | 2012 | 644 | 0.460 |
Why?
|
| India | 9 | 2021 | 301 | 0.460 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2014 | 986 | 0.460 |
Why?
|
| Benzhydryl Compounds | 3 | 2018 | 85 | 0.450 |
Why?
|
| MicroRNAs | 5 | 2020 | 2947 | 0.450 |
Why?
|
| Spine | 1 | 2014 | 293 | 0.440 |
Why?
|
| Drug Therapy, Combination | 10 | 2018 | 2315 | 0.440 |
Why?
|
| Purines | 1 | 2014 | 273 | 0.440 |
Why?
|
| Lipogenesis | 1 | 2012 | 76 | 0.430 |
Why?
|
| Trachea | 1 | 2014 | 259 | 0.430 |
Why?
|
| Cardiotonic Agents | 2 | 2016 | 151 | 0.430 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10331 | 0.420 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 2195 | 0.420 |
Why?
|
| Eye Injuries, Penetrating | 3 | 2017 | 23 | 0.420 |
Why?
|
| Adolescent | 22 | 2021 | 31252 | 0.410 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 973 | 0.410 |
Why?
|
| Nasolacrimal Duct | 3 | 2018 | 53 | 0.410 |
Why?
|
| Nitric Oxide Synthase | 2 | 2010 | 314 | 0.410 |
Why?
|
| Carotid Arteries | 1 | 2013 | 240 | 0.400 |
Why?
|
| Up-Regulation | 3 | 2014 | 2450 | 0.400 |
Why?
|
| Obesity | 6 | 2018 | 2884 | 0.390 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 1054 | 0.390 |
Why?
|
| Retrospective Studies | 16 | 2023 | 37905 | 0.390 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 196 | 0.390 |
Why?
|
| Cicatrix | 2 | 2023 | 208 | 0.380 |
Why?
|
| Esophagus | 1 | 2014 | 553 | 0.380 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2020 | 21 | 0.380 |
Why?
|
| Ophthalmologic Surgical Procedures | 5 | 2020 | 177 | 0.370 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2018 | 60 | 0.370 |
Why?
|
| Muscle Cells | 1 | 2010 | 38 | 0.370 |
Why?
|
| Acyl Coenzyme A | 2 | 2010 | 33 | 0.360 |
Why?
|
| Fibroblast Growth Factors | 1 | 2011 | 257 | 0.360 |
Why?
|
| Mutation | 4 | 2021 | 15179 | 0.360 |
Why?
|
| Treatment Outcome | 18 | 2020 | 32848 | 0.360 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 3719 | 0.350 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 3 | 2014 | 8 | 0.350 |
Why?
|
| Thinness | 1 | 2010 | 82 | 0.350 |
Why?
|
| Dipeptidyl Peptidase 4 | 3 | 2019 | 54 | 0.350 |
Why?
|
| Diagnosis, Differential | 12 | 2018 | 4744 | 0.350 |
Why?
|
| Aspergillosis | 2 | 2022 | 246 | 0.350 |
Why?
|
| Prednisolone | 4 | 2018 | 123 | 0.350 |
Why?
|
| Quinazolines | 1 | 2014 | 923 | 0.340 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2020 | 430 | 0.340 |
Why?
|
| Proteins | 4 | 2004 | 1963 | 0.340 |
Why?
|
| Tetrazoles | 3 | 2014 | 106 | 0.330 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3552 | 0.330 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2019 | 112 | 0.330 |
Why?
|
| Quality of Life | 1 | 2022 | 4532 | 0.320 |
Why?
|
| Myocardium | 6 | 2020 | 1313 | 0.320 |
Why?
|
| Adenocarcinoma, Sebaceous | 3 | 2019 | 65 | 0.320 |
Why?
|
| Carcinoma, Adenoid Cystic | 3 | 2021 | 421 | 0.320 |
Why?
|
| Ophthalmology | 2 | 2021 | 198 | 0.320 |
Why?
|
| Adamantane | 2 | 2018 | 31 | 0.310 |
Why?
|
| Glucocorticoids | 3 | 2018 | 629 | 0.310 |
Why?
|
| Tertiary Care Centers | 2 | 2022 | 403 | 0.310 |
Why?
|
| Suture Techniques | 2 | 2020 | 319 | 0.310 |
Why?
|
| Linagliptin | 2 | 2019 | 4 | 0.310 |
Why?
|
| Glucose Tolerance Test | 6 | 2010 | 213 | 0.300 |
Why?
|
| Dipeptides | 2 | 2018 | 91 | 0.300 |
Why?
|
| Myocytes, Cardiac | 4 | 2017 | 764 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 5539 | 0.290 |
Why?
|
| Reflex, Abnormal | 2 | 2018 | 20 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 849 | 0.290 |
Why?
|
| Oxazoles | 2 | 2017 | 60 | 0.280 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 13658 | 0.280 |
Why?
|
| Sulfonamides | 2 | 2014 | 1823 | 0.280 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2021 | 376 | 0.280 |
Why?
|
| Dyslipidemias | 1 | 2009 | 235 | 0.280 |
Why?
|
| Eye | 2 | 2022 | 301 | 0.280 |
Why?
|
| Triglycerides | 5 | 2012 | 603 | 0.280 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 128 | 0.270 |
Why?
|
| Thiophenes | 2 | 2017 | 148 | 0.270 |
Why?
|
| Ultrasonography | 5 | 2018 | 1863 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2011 | 624 | 0.250 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2021 | 15 | 0.250 |
Why?
|
| Aged | 23 | 2021 | 70117 | 0.250 |
Why?
|
| Hormones, Ectopic | 1 | 2004 | 10 | 0.250 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 196 | 0.250 |
Why?
|
| Animals | 26 | 2021 | 59536 | 0.240 |
Why?
|
| Albendazole | 3 | 2018 | 28 | 0.240 |
Why?
|
| Optic Nerve | 2 | 2023 | 133 | 0.240 |
Why?
|
| Rare Diseases | 3 | 2022 | 351 | 0.230 |
Why?
|
| Eye, Artificial | 1 | 2023 | 16 | 0.230 |
Why?
|
| Splanchnic Circulation | 1 | 2003 | 53 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2021 | 830 | 0.230 |
Why?
|
| Smoking | 1 | 2012 | 2440 | 0.230 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 48 | 0.230 |
Why?
|
| Cadherins | 3 | 2017 | 660 | 0.230 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 14889 | 0.230 |
Why?
|
| Sutures | 2 | 2020 | 86 | 0.220 |
Why?
|
| Muscles | 2 | 2004 | 416 | 0.220 |
Why?
|
| Receptors, Glucagon | 4 | 2012 | 36 | 0.220 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2022 | 6 | 0.220 |
Why?
|
| Body Weight | 3 | 2012 | 1293 | 0.220 |
Why?
|
| Cyclin B1 | 1 | 2022 | 56 | 0.210 |
Why?
|
| Viscera | 1 | 2002 | 81 | 0.210 |
Why?
|
| Visual Acuity | 4 | 2019 | 873 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Dermatofibrosarcoma | 1 | 2022 | 72 | 0.210 |
Why?
|
| Pyrimidines | 1 | 2014 | 3518 | 0.210 |
Why?
|
| Ketosis | 1 | 2021 | 16 | 0.210 |
Why?
|
| Taenia solium | 1 | 2021 | 7 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Melanoma | 5 | 2020 | 5317 | 0.200 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 216 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 1533 | 0.200 |
Why?
|
| Eye Diseases | 1 | 2023 | 132 | 0.200 |
Why?
|
| Mannans | 1 | 2021 | 31 | 0.200 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2019 | 224 | 0.190 |
Why?
|
| Saccharum | 1 | 2020 | 10 | 0.190 |
Why?
|
| Ethmoid Sinus | 1 | 2020 | 27 | 0.190 |
Why?
|
| Pandemics | 2 | 2020 | 1559 | 0.190 |
Why?
|
| Signal Transduction | 13 | 2020 | 11965 | 0.190 |
Why?
|
| Body Mass Index | 5 | 2011 | 2203 | 0.190 |
Why?
|
| Adipocytes, Brown | 1 | 2020 | 32 | 0.190 |
Why?
|
| Electroacupuncture | 1 | 2020 | 35 | 0.190 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 1143 | 0.190 |
Why?
|
| Mitochondria | 2 | 2004 | 1282 | 0.190 |
Why?
|
| Cells, Cultured | 8 | 2020 | 5637 | 0.190 |
Why?
|
| Fasting | 4 | 2017 | 349 | 0.190 |
Why?
|
| Hypoglycemia | 3 | 2014 | 213 | 0.180 |
Why?
|
| Administration, Topical | 1 | 2020 | 257 | 0.180 |
Why?
|
| Wounds, Penetrating | 1 | 2020 | 89 | 0.180 |
Why?
|
| Accidents, Traffic | 1 | 2020 | 116 | 0.180 |
Why?
|
| Time Factors | 12 | 2018 | 12926 | 0.180 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2021 | 136 | 0.180 |
Why?
|
| Infant | 8 | 2020 | 13310 | 0.180 |
Why?
|
| Phosphorylation | 6 | 2020 | 4804 | 0.180 |
Why?
|
| Blepharoplasty | 1 | 2020 | 36 | 0.180 |
Why?
|
| Hemangioma | 1 | 2021 | 154 | 0.180 |
Why?
|
| Adipocytes, White | 2 | 2020 | 34 | 0.180 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2020 | 112 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2020 | 2054 | 0.180 |
Why?
|
| Mucous Membrane | 1 | 2020 | 271 | 0.180 |
Why?
|
| Cyclin D1 | 1 | 2022 | 576 | 0.180 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 218 | 0.180 |
Why?
|
| Liposarcoma | 1 | 2021 | 214 | 0.170 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 2283 | 0.170 |
Why?
|
| Lymphangioma | 1 | 2019 | 36 | 0.170 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2016 | 63 | 0.170 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 6 | 0.170 |
Why?
|
| Propranolol | 1 | 2019 | 156 | 0.170 |
Why?
|
| Kidney | 2 | 2018 | 2146 | 0.170 |
Why?
|
| Eyelashes | 1 | 2018 | 3 | 0.170 |
Why?
|
| Administration, Ophthalmic | 1 | 2018 | 5 | 0.170 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 603 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 661 | 0.170 |
Why?
|
| Cleft Palate | 1 | 2020 | 128 | 0.170 |
Why?
|
| Cleft Lip | 1 | 2020 | 127 | 0.170 |
Why?
|
| Thiazoles | 1 | 2003 | 726 | 0.170 |
Why?
|
| Adipose Tissue, Brown | 2 | 2017 | 112 | 0.160 |
Why?
|
| Prognosis | 7 | 2023 | 21713 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 248 | 0.160 |
Why?
|
| Histoplasma | 1 | 2018 | 32 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2022 | 2803 | 0.160 |
Why?
|
| Conjunctivitis | 1 | 2018 | 31 | 0.160 |
Why?
|
| Echinococcosis | 1 | 2018 | 15 | 0.160 |
Why?
|
| Antiprotozoal Agents | 1 | 2018 | 40 | 0.160 |
Why?
|
| Child, Preschool | 8 | 2020 | 16273 | 0.160 |
Why?
|
| Endemic Diseases | 1 | 2018 | 67 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 9 | 2021 | 6942 | 0.160 |
Why?
|
| Diplopia | 1 | 2018 | 66 | 0.160 |
Why?
|
| Salivary Ducts | 1 | 2018 | 56 | 0.160 |
Why?
|
| Vimentin | 1 | 2019 | 253 | 0.160 |
Why?
|
| Conjunctival Diseases | 1 | 2018 | 37 | 0.160 |
Why?
|
| Bleomycin | 1 | 2019 | 467 | 0.160 |
Why?
|
| Histoplasmosis | 1 | 2018 | 74 | 0.160 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2019 | 148 | 0.160 |
Why?
|
| Heart | 2 | 2016 | 1223 | 0.150 |
Why?
|
| Myocardial Infarction | 4 | 2019 | 1374 | 0.150 |
Why?
|
| Eye Infections, Fungal | 1 | 2018 | 71 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 2 | 2011 | 153 | 0.150 |
Why?
|
| Immunohistochemistry | 9 | 2021 | 7548 | 0.150 |
Why?
|
| Cold Temperature | 1 | 2017 | 121 | 0.150 |
Why?
|
| Thermogenesis | 1 | 2017 | 46 | 0.150 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 92 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 187 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 323 | 0.150 |
Why?
|
| Myxoma | 1 | 2017 | 63 | 0.150 |
Why?
|
| Cysts | 2 | 2019 | 197 | 0.150 |
Why?
|
| Orbital Fractures | 1 | 2017 | 42 | 0.150 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 227 | 0.150 |
Why?
|
| Hyperglycemia | 3 | 2017 | 333 | 0.150 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 119 | 0.150 |
Why?
|
| Liraglutide | 1 | 2016 | 16 | 0.150 |
Why?
|
| Weight Gain | 2 | 2014 | 464 | 0.140 |
Why?
|
| Biomarkers | 4 | 2020 | 5047 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2013 | 421 | 0.140 |
Why?
|
| Emergency Treatment | 1 | 2017 | 105 | 0.140 |
Why?
|
| Mice | 13 | 2021 | 34495 | 0.140 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 113 | 0.140 |
Why?
|
| Vitreous Body | 1 | 2016 | 123 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 2594 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 771 | 0.140 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2017 | 142 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 677 | 0.140 |
Why?
|
| Consensus | 1 | 2020 | 978 | 0.140 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2018 | 489 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 544 | 0.140 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 239 | 0.140 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 183 | 0.140 |
Why?
|
| Protective Agents | 1 | 2016 | 51 | 0.140 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2017 | 176 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 476 | 0.130 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2018 | 116 | 0.130 |
Why?
|
| Sclerosis | 1 | 2015 | 84 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2019 | 649 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 2992 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 144 | 0.130 |
Why?
|
| Nose | 1 | 2017 | 192 | 0.130 |
Why?
|
| RNA Interference | 3 | 2017 | 1408 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2023 | 3981 | 0.130 |
Why?
|
| Craniocerebral Trauma | 1 | 2016 | 130 | 0.130 |
Why?
|
| RNA, Messenger | 5 | 2015 | 6150 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 1910 | 0.130 |
Why?
|
| Cyclic AMP | 2 | 2012 | 358 | 0.130 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 501 | 0.130 |
Why?
|
| Rosuvastatin Calcium | 1 | 2014 | 43 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 1823 | 0.130 |
Why?
|
| Global Health | 1 | 2020 | 657 | 0.130 |
Why?
|
| Diet, Western | 1 | 2014 | 23 | 0.130 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2015 | 93 | 0.130 |
Why?
|
| Dietary Fats | 2 | 2008 | 339 | 0.130 |
Why?
|
| Fibroblasts | 2 | 2018 | 1682 | 0.130 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 7222 | 0.130 |
Why?
|
| Drainage | 2 | 2014 | 416 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 7702 | 0.120 |
Why?
|
| Debridement | 1 | 2015 | 123 | 0.120 |
Why?
|
| Curettage | 1 | 2014 | 22 | 0.120 |
Why?
|
| Equipment Design | 1 | 2018 | 1204 | 0.120 |
Why?
|
| Pain | 1 | 2022 | 1658 | 0.120 |
Why?
|
| Skin Transplantation | 1 | 2015 | 173 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2018 | 1113 | 0.120 |
Why?
|
| Polyethylene | 1 | 2013 | 19 | 0.120 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4654 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 1084 | 0.110 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2013 | 115 | 0.110 |
Why?
|
| Intubation | 1 | 2013 | 40 | 0.110 |
Why?
|
| Orbital Cellulitis | 1 | 2013 | 18 | 0.110 |
Why?
|
| Biopsy | 6 | 2021 | 3443 | 0.110 |
Why?
|
| Energy Metabolism | 2 | 2018 | 992 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 3203 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 10035 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 353 | 0.110 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 220 | 0.110 |
Why?
|
| Alkylating Agents | 1 | 2012 | 78 | 0.110 |
Why?
|
| Retina | 2 | 2013 | 532 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2013 | 234 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 430 | 0.110 |
Why?
|
| Apoptosis | 5 | 2020 | 7591 | 0.110 |
Why?
|
| Eye Infections, Bacterial | 1 | 2013 | 96 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 29902 | 0.100 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 423 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 8873 | 0.100 |
Why?
|
| DNA Damage | 1 | 2020 | 1954 | 0.100 |
Why?
|
| Mitomycin | 1 | 2012 | 208 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2023 | 5542 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.100 |
Why?
|
| Ubiquitin | 1 | 2013 | 344 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2014 | 318 | 0.100 |
Why?
|
| Disease Progression | 3 | 2019 | 6682 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2017 | 1987 | 0.100 |
Why?
|
| Epinephrine | 3 | 2021 | 255 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2014 | 1391 | 0.100 |
Why?
|
| Human papillomavirus 16 | 1 | 2012 | 256 | 0.100 |
Why?
|
| Hepatocytes | 1 | 2013 | 351 | 0.100 |
Why?
|
| Logistic Models | 1 | 2018 | 3441 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 178 | 0.090 |
Why?
|
| Reference Values | 5 | 2004 | 1099 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 862 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 4975 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 589 | 0.090 |
Why?
|
| Diglycerides | 1 | 2010 | 37 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2014 | 2588 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2012 | 694 | 0.090 |
Why?
|
| Edema | 1 | 2011 | 267 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2014 | 426 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8223 | 0.090 |
Why?
|
| Nausea | 1 | 2011 | 525 | 0.090 |
Why?
|
| C-Peptide | 3 | 2007 | 107 | 0.090 |
Why?
|
| Injections, Intralesional | 2 | 2019 | 164 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2012 | 837 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 550 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2013 | 519 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2004 | 1538 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1148 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2011 | 299 | 0.080 |
Why?
|
| Texas | 3 | 2012 | 6311 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 548 | 0.080 |
Why?
|
| Helper Viruses | 1 | 2008 | 55 | 0.080 |
Why?
|
| Hormones | 4 | 2007 | 266 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 778 | 0.080 |
Why?
|
| beta Catenin | 1 | 2012 | 688 | 0.080 |
Why?
|
| Disease Management | 1 | 2014 | 1052 | 0.080 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 980 | 0.080 |
Why?
|
| Triazoles | 1 | 2012 | 617 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 1011 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2015 | 927 | 0.080 |
Why?
|
| Leptin | 2 | 2013 | 295 | 0.080 |
Why?
|
| Glucagon | 2 | 2006 | 196 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 3472 | 0.080 |
Why?
|
| Receptors, Adiponectin | 2 | 2004 | 12 | 0.080 |
Why?
|
| Anthelmintics | 2 | 2018 | 69 | 0.080 |
Why?
|
| Adipose Tissue, White | 2 | 2018 | 99 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1301 | 0.080 |
Why?
|
| Eating | 2 | 2008 | 421 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 368 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2015 | 1664 | 0.070 |
Why?
|
| Cholesterol | 3 | 2012 | 658 | 0.070 |
Why?
|
| Fenofibrate | 1 | 2007 | 57 | 0.070 |
Why?
|
| Free Radical Scavengers | 1 | 2007 | 80 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2013 | 732 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2010 | 644 | 0.070 |
Why?
|
| Carcinoma | 1 | 2018 | 2578 | 0.070 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 213 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 395 | 0.070 |
Why?
|
| Gastric Emptying | 1 | 2006 | 94 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4549 | 0.070 |
Why?
|
| Antifungal Agents | 2 | 2022 | 834 | 0.070 |
Why?
|
| Fat Emulsions, Intravenous | 2 | 2003 | 70 | 0.070 |
Why?
|
| Fibrosis | 2 | 2020 | 793 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2006 | 154 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 330 | 0.060 |
Why?
|
| Adenylate Kinase | 1 | 2004 | 36 | 0.060 |
Why?
|
| Resistin | 1 | 2004 | 39 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 461 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2173 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 235 | 0.060 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 181 | 0.060 |
Why?
|
| Models, Biological | 1 | 2012 | 3254 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2008 | 1459 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1742 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2019 | 1544 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2004 | 341 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2018 | 1764 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 343 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2017 | 5710 | 0.050 |
Why?
|
| Mexican Americans | 1 | 2004 | 322 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2012 | 234 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6207 | 0.050 |
Why?
|
| Syndrome | 2 | 2017 | 1351 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2004 | 448 | 0.050 |
Why?
|
| Corticosterone | 1 | 2021 | 119 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 573 | 0.050 |
Why?
|
| Streptozocin | 1 | 2021 | 75 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 554 | 0.050 |
Why?
|
| Ketones | 1 | 2021 | 54 | 0.050 |
Why?
|
| Galactose | 1 | 2021 | 87 | 0.050 |
Why?
|
| Osmolar Concentration | 3 | 2007 | 204 | 0.050 |
Why?
|
| Voriconazole | 1 | 2021 | 108 | 0.050 |
Why?
|
| Organelle Biogenesis | 1 | 2020 | 32 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2008 | 1616 | 0.050 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2020 | 52 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 2049 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 3045 | 0.050 |
Why?
|
| Epithelioid Cells | 1 | 2020 | 43 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 764 | 0.040 |
Why?
|
| Transfection | 2 | 2017 | 2944 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1038 | 0.040 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 27 | 0.040 |
Why?
|
| Collagen | 2 | 2018 | 752 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 565 | 0.040 |
Why?
|
| Water | 1 | 2021 | 361 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2004 | 1620 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 630 | 0.040 |
Why?
|
| Awareness | 1 | 1999 | 126 | 0.040 |
Why?
|
| Prolapse | 1 | 2018 | 13 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 347 | 0.040 |
Why?
|
| Taenia | 1 | 2018 | 13 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 161 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 429 | 0.040 |
Why?
|
| Cysticercus | 1 | 2017 | 5 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2018 | 156 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 886 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2018 | 600 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 621 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 698 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2017 | 104 | 0.040 |
Why?
|
| Cytoprotection | 1 | 2017 | 66 | 0.040 |
Why?
|
| Cytochromes c | 1 | 2017 | 118 | 0.040 |
Why?
|
| Calibration | 1 | 2018 | 337 | 0.040 |
Why?
|
| Metals | 1 | 2017 | 155 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2018 | 197 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 478 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 4938 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 241 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 10001 | 0.040 |
Why?
|
| Environment | 1 | 2017 | 190 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 558 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 1382 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 311 | 0.030 |
Why?
|
| Diet | 1 | 2004 | 1440 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2017 | 471 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 726 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2015 | 42 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2018 | 2669 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 698 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 487 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 5159 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8865 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 577 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 748 | 0.030 |
Why?
|
| Surgery, Plastic | 1 | 2020 | 344 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2017 | 492 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 709 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 4892 | 0.030 |
Why?
|
| Esthetics | 1 | 2015 | 189 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12221 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 1335 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 216 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 2307 | 0.030 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 667 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2006 | 7226 | 0.030 |
Why?
|
| Lymphoscintigraphy | 1 | 2013 | 35 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 2074 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 300 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2013 | 67 | 0.030 |
Why?
|
| Amblyopia | 1 | 2013 | 112 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 86 | 0.030 |
Why?
|
| Eye Movements | 1 | 2013 | 116 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2012 | 90 | 0.030 |
Why?
|
| Metronidazole | 1 | 2013 | 149 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2013 | 355 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2012 | 116 | 0.030 |
Why?
|
| Refractive Errors | 1 | 2013 | 95 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 409 | 0.030 |
Why?
|
| Photography | 1 | 2013 | 139 | 0.030 |
Why?
|
| Choroid | 1 | 2012 | 35 | 0.030 |
Why?
|
| Eye Enucleation | 1 | 2012 | 91 | 0.030 |
Why?
|
| Strabismus | 1 | 2013 | 213 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 3438 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 925 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 311 | 0.030 |
Why?
|
| Vancomycin | 1 | 2013 | 273 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 2809 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 798 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1129 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9180 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4314 | 0.020 |
Why?
|
| Developing Countries | 1 | 2012 | 315 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 2216 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2171 | 0.020 |
Why?
|
| Human Growth Hormone | 2 | 1999 | 82 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1999 | 156 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 4109 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 1904 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2013 | 1005 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 3639 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 4113 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 6869 | 0.020 |
Why?
|
| Hydrocortisone | 2 | 1999 | 388 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 4757 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 5377 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 5673 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3536 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3570 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2013 | 1415 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 5114 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 1959 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3101 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 191 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 1399 | 0.020 |
Why?
|
| Systole | 1 | 2004 | 196 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 231 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 542 | 0.010 |
Why?
|
| Emulsions | 1 | 2003 | 82 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 4844 | 0.010 |
Why?
|
| Soybean Oil | 1 | 2003 | 66 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6100 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 1694 | 0.010 |
Why?
|
| Phospholipids | 1 | 2003 | 177 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 60 | 0.010 |
Why?
|
| Tritium | 1 | 2002 | 200 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 769 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2819 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 153 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2002 | 157 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 597 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 587 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 717 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 2139 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 1171 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 2508 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1648 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1998 | 272 | 0.010 |
Why?
|
| Perception | 1 | 1999 | 350 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7789 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 1546 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 2522 | 0.010 |
Why?
|
| Homeostasis | 1 | 1998 | 950 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 5270 | 0.010 |
Why?
|